Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mesa Laboratories stock

Own Mesa Laboratories stock in just a few minutes.

Mesa Laboratories, Inc is a scientific & technical instruments business based in the US. Mesa Laboratories shares (MLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Mesa Laboratories employs 460 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Mesa Laboratories

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MLAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mesa Laboratories share price

Use our graph to track the performance of MLAB stocks over time.

Mesa Laboratories shares at a glance

Information last updated 2021-04-23.
52-week range$207.17 - $307.79
50-day moving average $253.18
200-day moving average $272.50
Wall St. target price$273.00
PE ratio 736.3871
Dividend yield $0.64 (0.25%)
Earnings per share (TTM) $0.31

Buy Mesa Laboratories shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mesa Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Mesa Laboratories under- or over-valued?

Valuing Mesa Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mesa Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Mesa Laboratories's P/E ratio

Mesa Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 736x. In other words, Mesa Laboratories shares trade at around 736x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Mesa Laboratories's EBITDA

Mesa Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.7 million.

The EBITDA is a measure of a Mesa Laboratories's overall financial performance and is widely used to measure a its profitability.

Mesa Laboratories financials

Revenue TTM $130.2 million
Operating margin TTM 10.18%
Gross profit TTM $73.4 million
Return on assets TTM 1.59%
Return on equity TTM -0.81%
Profit margin -2.02%
Book value $80.45
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Mesa Laboratories shares

There are currently 281,654 Mesa Laboratories shares held short by investors – that's known as Mesa Laboratories's "short interest". This figure is 3.2% down from 291,104 last month.

There are a few different ways that this level of interest in shorting Mesa Laboratories shares can be evaluated.

Mesa Laboratories's "short interest ratio" (SIR)

Mesa Laboratories's "short interest ratio" (SIR) is the quantity of Mesa Laboratories shares currently shorted divided by the average quantity of Mesa Laboratories shares traded daily (recently around 32079.043280182). Mesa Laboratories's SIR currently stands at 8.78. In other words for every 100,000 Mesa Laboratories shares traded daily on the market, roughly 8780 shares are currently held short.

However Mesa Laboratories's short interest can also be evaluated against the total number of Mesa Laboratories shares, or, against the total number of tradable Mesa Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mesa Laboratories's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Mesa Laboratories shares in existence, roughly 50 shares are currently held short) or 0.0685% of the tradable shares (for every 100,000 tradable Mesa Laboratories shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mesa Laboratories.

Find out more about how you can short Mesa Laboratories stock.

Mesa Laboratories share dividends


Dividend payout ratio: 12.38% of net profits

Recently Mesa Laboratories has paid out, on average, around 12.38% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Mesa Laboratories shareholders could enjoy a 0.25% return on their shares, in the form of dividend payments. In Mesa Laboratories's case, that would currently equate to about $0.64 per share.

While Mesa Laboratories's payout ratio might seem low, this can signify that Mesa Laboratories is investing more in its future growth.

Mesa Laboratories's most recent dividend payout was on 14 June 2021. The latest dividend was paid out to all shareholders who bought their shares by 26 May 2021 (the "ex-dividend date").

Mesa Laboratories share price volatility

Over the last 12 months, Mesa Laboratories's shares have ranged in value from as little as $207.165 up to $307.7932. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mesa Laboratories's is 0.3502. This would suggest that Mesa Laboratories's shares are less volatile than average (for this exchange).

Mesa Laboratories overview

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services. This segment also provides chemical and cleaning indicators that are used to assess the effectiveness of sterilization and cleaning processes. Its Instruments segment offers data loggers used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air sampling; and torque testing systems used for measure bottle cap tightness. This segment's products are used in healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and environmental air sampling industries. The company's Biopharmaceutical Development segment develops, manufactures, and commercializes automated solutions for protein analysis, which include analysis equipment, CDs, kits, and buffers; and peptide synthesizers to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site